T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Franklin Electric
FELE
$4.68B
| $158M | 0.03% |
3,913,608
+418,176
| +12% | +$16.6M |
|
|
RAVN
502
DELISTED
Raven Industries Inc
RAVN
| $157M | 0.03% |
4,745,900
| – | – |
|
503
New York Times
NYT
$10.3B
| $157M | 0.03% |
10,316,400
-14,200
| -0.1% | -$222K |
|
504
Cameco
CCJ
$42.6B
| $157M | 0.03% |
8,000,800
+4,441,700
| +125% | +$92.7M |
|
505
Belden
BDC
$5.36B
| $157M | 0.03% |
2,002,523
+950
| +0% | +$69.7K |
|
506
Home BancShares
HOMB
$6.27B
| $156M | 0.03% |
9,522,716
-31,960
| -0.3% | -$515K |
|
507
CenterPoint Energy
CNP
$26.7B
| $154M | 0.03% |
6,046,780
-2,069,187
| -25% | -$50.2M |
|
|
EE
508
DELISTED
El Paso Electric Company
EE
| $153M | 0.03% |
3,809,400
+20
| +0% | +$745 |
|
509
Mettler-Toledo International
MTD
$28.7B
| $152M | 0.03% |
601,858
+46,385
| +8% | +$11.1M |
|
510
Neurocrine Biosciences
NBIX
$15.3B
| $152M | 0.03% |
10,255,239
-1,700
| -0% | -$24K |
|
511
The Mosaic Company
MOS
$6.92B
| $152M | 0.03% |
3,068,495
+809,295
| +36% | +$39.9M |
|
|
MNK
512
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $151M | 0.03% |
1,884,447
+539,294
| +40% | +$39.1M |
|
513
Zillow
ZG
$8.15B
| $151M | 0.03% |
3,164,430
+166,500
| +6% | +$6.11M |
|
|
SINA
514
DELISTED
Sina Corp
SINA
| $151M | 0.03% |
3,024,335
-1,222,271
| -29% | -$60M |
|
515
Republic Services
RSG
$65.9B
| $149M | 0.03% |
3,928,503
+468,309
| +14% | +$16.6M |
|
516
T-Mobile US
TMUS
$197B
| $148M | 0.03% |
4,410,251
+358,268
| +9% | +$11.6M |
|
517
DuPont de Nemours
DD
$19.5B
| $148M | 0.03% |
1,133,776
+8,430
| +0.7% | +$1.07M |
|
518
Bread Financial
BFH
$4.51B
| $147M | 0.03% |
656,647
-1,285,603
| -66% | -$262M |
|
|
ICPT
519
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $147M | 0.03% |
622,030
+54,390
| +10% | +$14.3M |
|
520
Kemper
KMPR
$1.59B
| $147M | 0.03% |
3,989,588
+170,420
| +4% | +$6.31M |
|
|
CBL
521
DELISTED
CBL& Associates Properties, Inc.
CBL
| $146M | 0.03% |
7,690,608
-180,683
| -2% | -$3.34M |
|
522
IPG Photonics
IPGP
$3.57B
| $146M | 0.03% |
2,115,830
-729,200
| -26% | -$49.1M |
|
523
Jack in the Box
JACK
$358M
| $145M | 0.03% |
2,422,350
-208,140
| -8% | -$11.9M |
|
524
Innospec
IOSP
$2.31B
| $145M | 0.03% |
3,355,080
+40,186
| +1% | +$1.73M |
|
|
AVNR
525
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $144M | 0.03% |
25,556,122
-97,620
| -0.4% | -$450K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.